
    
      PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are randomly assigned to
      oral 3,4-diaminopyridine (3,4-DAP) or placebo administered for 4 days. After a washout of at
      least 5 days, patients cross to the alternate therapy for 4 days.
    
  